SCHEMBL5581899

SCHEMBL5581899

N#CC(O)c1ccccn1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.49
MEN1 O00255 1/20 0.49
GAA P10253 1/20 0.49
KMT2A Q03164 1/20 0.49
TSHR P16473 2/20 0.48
SLC6A2 P23975 1/20 0.45
SLC6A4 P31645 1/20 0.45
SLC6A3 Q01959 1/20 0.45
KDM4E B2RXH2 1/20 0.44
KCNA5 P22460 5/20 0.40
MAPT P10636 1/20 0.40
KCNE1 P15382 1/20 0.40
TP53 P04637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 1/20 0.39
ALDH1A1 P00352 2/20 0.38
KCNH2 Q12809 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9547890 0.83 SLC6A2 (0.48) SMN1; SMN2MEN1GAAKMT2ATSHR
SCHEMBL30321098 0.79 SLC6A2 (0.45) SMN1; SMN2MEN1GAAKMT2ATSHR
SCHEMBL22744059 0.79 SLC6A2 (0.45) SMN1; SMN2MEN1GAAKMT2ATSHR
SCHEMBL9331327 0.79 SLC6A2 (0.45) SMN1; SMN2MEN1GAAKMT2ATSHR
SCHEMBL3758698 0.79 SLC6A2 (0.45) SMN1; SMN2MEN1GAAKMT2ATSHR
SCHEMBL5429300 0.78 SLC6A2 (0.48) SMN1; SMN2MEN1GAAKMT2ATSHR
SCHEMBL2937192 0.78 SLC6A2 (0.48) SMN1; SMN2MEN1GAAKMT2ATSHR
SCHEMBL27828227 0.76 SLC6A3 (0.42) SMN1; SMN2MEN1GAAKMT2ATSHR
SCHEMBL22275828 0.75 SMN1; SMN2 (0.49) SMN1; SMN2MEN1GAAKMT2ATSHR
SCHEMBL29700907 0.75 SMN1; SMN2 (0.49) SMN1; SMN2MEN1GAAKMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570626-B2 Degraders and degrons for targeted protein degradation C4 THERAPEUTICS, INC. (US) 2026-03-10 US disclosed
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-11-09 US disclosed
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-11-09 US disclosed
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-11-09 US disclosed
US-11524949-B2 Degraders and Degrons for targeted protein degradation C4 THERAPEUTICS, INC. (US) 2022-12-13 US disclosed
US-11524949-B2 Degraders and Degrons for targeted protein degradation C4 THERAPEUTICS, INC. (US) 2022-12-13 US disclosed
US-20220251061-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2022-08-11 US disclosed
EP-3710002-A2 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION C4 Therapeutics, Inc. (US) 2020-09-23 EP disclosed
CN-111372585-A Degradants and degreddeterminants for target protein degradation C4医药公司 2020-07-03 CN disclosed
US-9315792-B2 Nitrilases, nucleic acids encoding them and methods for making and using them BASF ENZYMES LLC (US) 2016-04-19 US disclosed
EP-0711836-B1 Method of producing optically active alpha-hydroxy acid or alpha-hydroxyamide MITSUBISHI RAYON CO (JP) 2000-02-02 EP disclosed
US-5756306-A HYDROLYSIS OF COMPOUNDS USING MICROORGAMISMS TO FORM ALPHA HYDROXY ACIDS OR AMIDES NITTO CHEMICAL INDUSTRY CO., LTD. (JP) 1998-05-26 US disclosed
US-5736385-A NITRILASE OR NITRILE HYDRATASE HYDROLYSIS OF A CYANOHYDRIN WHILE AUTOMATICALLY CONTROLLING CYANOHYDRIN CONCENTRATION NITTO CHEMICAL INDUSTRY CO., LTD. (JP) 1998-04-07 US disclosed
EP-0773297-A2 Process for producing alfa-hydroxy acid or alfa-hydroxyamide by microorganism NITTO CHEMICAL INDUSTRY CO., LTD. (JP) 1997-05-14 EP disclosed
EP-0711836-A1 Method of producing optically active alpha-hydroxy acid or alpha-hydroxyamide NITTO CHEMICAL INDUSTRY CO., LTD. (JP) 1996-05-15 EP disclosed
US-5508181-A REACTING AN ALPHA-HYDROXYNITRILE (OR MIXTURE WITH AN ALDEHYDE) WITH HYDROGEN CYANIDE IN PRESENCE OF PHOSPHITE OR HYPOPHOSPHITE IONS NITTO CHEMICAL INDUSTRY CO., LTD. (JP) 1996-04-16 US disclosed
EP-0666320-A2 Process for producing alpha-hydroxy acid or alpha-hydroxyamide by microorganisms NITTO CHEMICAL INDUSTRY CO., LTD. (JP) 1995-08-09 EP disclosed
US-4511562-A (Thio)(dithio-phosphates(phosphonates), processes for their preparation, and their use in pest-combating agents BAYER AKTIENGESELLSCHAFT (DE) 1985-04-16 US disclosed
US-4429130-A Pyrid-2'-yl-2-trifluoromethyl quinol-4-ylmethanes BASF AKTIENGESELLSCHAFT (DE) 1984-01-31 US disclosed
EP-0072482-A2 (Thiono)(dithio)-phosphoric-(phosphonic)-acid esters, process for their preparation and their use as pesticides BAYER AG (DE) 1983-02-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570626-B2 Degraders and degrons for targeted protein degradation ADRM1, UCHL3, USP30 SMN1; SMN2 2370/4885MEN1 3901/4885GAA 1091/4885
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION STUB1, MDM2, USP30 SMN1; SMN2 1270/4885MEN1 1550/4885GAA 329/4885
US-20220251061-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION STUB1, MDM2, USP30 SMN1; SMN2 1270/4885MEN1 1550/4885GAA 329/4885
US-11524949-B2 Degraders and Degrons for targeted protein degradation STUB1, MDM2, USP30 SMN1; SMN2 1270/4885MEN1 1550/4885GAA 329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.